Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

Also called NCT05759078

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05759078
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05759078. Randomized; triple masking; primary purpose treatment. Start 2022-09-22 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
Acronym
INFERRCT
Condition
Myocardial Infarction, Acute
Intervention (Drug)
Ferinject
Intervention (Drug)
Sodium Chloride 0.9% Inj
Lead sponsor
Wroclaw Medical University (class: other)

Record details

Record id
cardio:ct-nct05759078
Content hash
7b947dc8ffb28e4ad8b2fe0d0de6f97e17eec9fd83c8f8ef7f969d1836dfd199